Sun Pharma, Cipla and More Fall As US Tariff Fears Drag Pharma Stocks; Nifty Pharma Down 3%

Pharmaceutical shares declined sharply, dragging the Nifty Pharma index down nearly 3%. Major companies like Sun Pharmaceutical Industries, Cipla, and Apollo Hospitals fell up to 4% during the day. The fall followed a report that the US may impose heavy tariffs on imported medicines.

What Triggered the Sell-Off in Pharma Stocks?

A report by the Financial Times suggested the US administration could introduce tariffs of up to 100% on certain imported drugs. The proposed duties may target companies that do not manufacture medicines in the US.
This created worries about:

• Higher export costs
• Supply chain disruptions
• Pressure to shift production to the US

The lack of clarity on which companies may be affected led investors to reduce exposure to pharma stocks.

Broad Decline Across Pharma and Healthcare Stocks

The fall was widespread across the sector. Several companies from pharma manufacturers to hospitals and healthcare service providers traded lower, showing that the impact was not limited to a few stocks but affected the entire industry sentiment.

Why Tariffs Are a Big Risk for Indian Pharma

The US is one of the largest markets for Indian pharmaceutical companies. If tariffs are imposed:

• Export margins may shrink
• Companies may need to invest in US manufacturing
• Earnings growth could slow in the near term

The tariff plan is linked to a national security investigation under US trade laws, which adds further uncertainty for drugmakers.

Also Read: March 2026 Auto Sales: Tata Motors Leads Growth, Mahindra Shows Stability Across Segments!

Conclusion

The possibility of steep US tariffs has created fresh uncertainty for the pharma sector. Until there is clarity on the policy and potential exemptions, investor caution is likely to continue, keeping pharma stocks under pressure in the near term.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.